210 related articles for article (PubMed ID: 29675587)
1. A Case of Gastric Neuroendocrine Neoplasm with Mixed Grade: a Distinct Type of "High"-grade Well-Differentiated Neuroendocrine Neoplasm.
Guadagno E; Luglio G; Iacobelli A; Borrelli G; Castaldi A; De Rosa G; Del Basso De Caro M
Endocr Pathol; 2018 Sep; 29(3):289-293. PubMed ID: 29675587
[TBL] [Abstract][Full Text] [Related]
2. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
Tang LH; Basturk O; Sue JJ; Klimstra DS
Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
[TBL] [Abstract][Full Text] [Related]
3. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.
Basturk O; Yang Z; Tang LH; Hruban RH; Adsay V; McCall CM; Krasinskas AM; Jang KT; Frankel WL; Balci S; Sigel C; Klimstra DS
Am J Surg Pathol; 2015 May; 39(5):683-90. PubMed ID: 25723112
[TBL] [Abstract][Full Text] [Related]
4. Are G3 ENETS neuroendocrine neoplasms heterogeneous?
Vélayoudom-Céphise FL; Duvillard P; Foucan L; Hadoux J; Chougnet CN; Leboulleux S; Malka D; Guigay J; Goere D; Debaere T; Caramella C; Schlumberger M; Planchard D; Elias D; Ducreux M; Scoazec JY; Baudin E
Endocr Relat Cancer; 2013 Oct; 20(5):649-57. PubMed ID: 23845449
[TBL] [Abstract][Full Text] [Related]
5. Comparison of World Health Organization 2000/2004 and World Health Organization 2010 classifications for gastrointestinal and pancreatic neuroendocrine tumors.
Pasaoglu E; Dursun N; Ozyalvacli G; Hacihasanoglu E; Behzatoglu K; Calay O
Ann Diagn Pathol; 2015 Apr; 19(2):81-7. PubMed ID: 25702616
[TBL] [Abstract][Full Text] [Related]
6. Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement.
Coriat R; Walter T; Terris B; Couvelard A; Ruszniewski P
Oncologist; 2016 Oct; 21(10):1191-1199. PubMed ID: 27401895
[TBL] [Abstract][Full Text] [Related]
7. G3 GEP NENs category: are basic and clinical investigations well integrated?
Milione M; Fazio N
Endocrine; 2018 Apr; 60(1):28-30. PubMed ID: 28733935
[TBL] [Abstract][Full Text] [Related]
8. Sporadic Gastric Well-Differentiated Neuroendocrine Tumors Have a Higher Ki-67 Proliferative Index.
Lee HE; Mounajjed T; Erickson LA; Wu TT
Endocr Pathol; 2016 Sep; 27(3):259-67. PubMed ID: 27306997
[TBL] [Abstract][Full Text] [Related]
9. [Consensus and controversy on subtype classification of gastric neuroendocrine neoplasms].
Tan H
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):977-981. PubMed ID: 28900986
[TBL] [Abstract][Full Text] [Related]
10. Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas.
Tang LH; Untch BR; Reidy DL; O'Reilly E; Dhall D; Jih L; Basturk O; Allen PJ; Klimstra DS
Clin Cancer Res; 2016 Feb; 22(4):1011-7. PubMed ID: 26482044
[TBL] [Abstract][Full Text] [Related]
11. Two cases of lung neuroendocrine carcinoma with carcinoid morphology.
Inafuku K; Yokose T; Ito H; Eriguchi D; Samejima J; Nagashima T; Nakayama H; Suzuki M; Yamada K; Masuda M
Diagn Pathol; 2019 Sep; 14(1):104. PubMed ID: 31511024
[TBL] [Abstract][Full Text] [Related]
12. [Clinicopathologic features and prognostic analysis of 240 patients with gastric neuroendocrine neoplasms].
Liang WQ; Zhang W; Qiao S; Wang BH; Wang C; Zhuang ZW; Xi HQ; Cai AZ; Wei B; Chen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Jan; 23(1):38-43. PubMed ID: 31958929
[No Abstract] [Full Text] [Related]
13. Neuroendocrine tumor G3: a pancreatic well-differentiated neuroendocrine tumor with a high proliferative rate.
Tanaka H; Matsusaki S; Baba Y; Isono Y; Kumazawa H; Sase T; Okano H; Saito T; Mukai K; Kaneko H
Clin J Gastroenterol; 2015 Dec; 8(6):414-20. PubMed ID: 26439620
[TBL] [Abstract][Full Text] [Related]
14. [The diagnosis and treatment of G3 neuroendocrine tumors according to the new NCCN guideline].
Liang Y; Yu XJ; Chen J
Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(14):982-987. PubMed ID: 35399015
[TBL] [Abstract][Full Text] [Related]
15. Management of Well-Differentiated High-Grade (G3) Neuroendocrine Tumors.
Sonbol MB; Halfdanarson TR
Curr Treat Options Oncol; 2019 Aug; 20(9):74. PubMed ID: 31428952
[TBL] [Abstract][Full Text] [Related]
16. Treatment landscape of advanced high-grade neuroendocrine neoplasms.
Alheraki SZ; Almquist DR; Starr JS; Halfdanarson TR; Sonbol MB
Clin Adv Hematol Oncol; 2023 Jan; 21(1):16-26. PubMed ID: 36638352
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological and genetic characteristics of gastric neuroendocrine tumour (NET) G3 and comparisons with neuroendocrine carcinoma and NET G2.
Chen S; Sun L; Chen H; Li J; Lu C; Yang Y; Sun Y
Histopathology; 2023 Nov; 83(5):700-711. PubMed ID: 37403531
[TBL] [Abstract][Full Text] [Related]
18. Neuroendocrine Cancer, Therapeutic Strategies in G3 Cancers.
Rinke A; Gress TM
Digestion; 2017; 95(2):109-114. PubMed ID: 28161703
[TBL] [Abstract][Full Text] [Related]
19. Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading.
Cavalcanti E; Armentano R; Valentini AM; Chieppa M; Caruso ML
Cell Death Dis; 2017 Aug; 8(8):e3004. PubMed ID: 28837143
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Evaluations Tailored to Specific Gastric Neuroendocrine Neoplasms: Analysis Of 200 Cases with Extended Follow-Up.
Vanoli A; La Rosa S; Miceli E; Klersy C; Maragliano R; Capuano F; Persichella A; Martino M; Inzani F; Luinetti O; Di Sabatino A; Sessa F; Paulli M; Corazza GR; Rindi G; Bordi C; Capella C; Solcia E
Neuroendocrinology; 2018; 107(2):114-126. PubMed ID: 29895024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
